Key questions in COVID-19 are the duration and determinants of infectious virus shedding.
Here, we report that infectious virus shedding is detected by virus cultures in 23 of the 129 …

The classical paradigm of tuberculosis (TB) immunity, with a central protective role for Th1
responses and IFN-γ-stimulated cellular responses, has been challenged by unsatisfactory …

Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs
are urgently needed. The landscape of TB treatment has changed considerably over the last …

Background Long-term shedding of viral RNA in COVID-19 prevents timely discharge from
the hospital or de-escalation of infection prevention and control practices. Key questions are …

Objectives The pharmacodynamics of tuberculosis (TB) treatment should be further explored,
to prevent emergence of resistance, treatment failure and relapse of infection. The …

There has been an increased interest in pharmacokinetics and pharmacodynamics (PKPD)
of anti-tuberculosis drugs. A better understanding of the relationship between drug exposure…

To determine differences in the ability of Mycobacterium tuberculosis strains to withstand
antituberculosis drug treatment, we compared the activity of antituberculosis drugs against …

Rationale: The dosage of 10 mg/kg/d rifampin, as currently used in the treatment of tuberculosis
(TB), is not an optimal dose. Shortening of treatment duration might be achievable using …

Background Despite intensive treatment regimens, the outcome of Mycobacterium abscessus
infections is extremely poor and thus novel treatment regimens are needed. Although …

Tuberculosis (TB) is still a major life-threatening infectious disease, within which especially
the rise of multidrug resistant TB (MDR-TB) is currently worrying. This study focuses on …